Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF COMMERCIAL OFFICER | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-03-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-03 · Exercise / conversion · Acquired 4,869 · Balance 4,869 Row 2 · 2025-03-03 · Sale · Disposed 4,369 · Balance 500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 500 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2030-03-04 | Direct | 0 |
Reported balance
After 2025-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-03 · Exercise / conversion · Disposed 4,869 · Balance 0 F4: The stock option vests in five equal annual installments beginning on March 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The stock option vests in five equal annual installments beginning on March 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 4,869 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-25-006919 · form4-03052025_040301.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,869 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on March 1, 2021. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 500 | $33.23 | $16,615.10 |
DisclosureSEC source: 0001415889-25-006919 · form4-03052025_040301.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,369 | $32.61 | $142,474.40 |
DisclosureSEC source: 0001415889-25-006919 · form4-03052025_040301.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 4,869 | $8.22 | $40,023.18 |
DisclosureSEC source: 0001415889-25-006919 · form4-03052025_040301.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,629 | $38.02 | $61,941.10 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · nonDerivative · entry 6 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.40. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 13,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · derivative · entry 10 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,450 Underlying: Common Stock · 13,450 shares Expires not disclosed F9 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F8 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F9 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 47,200 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · derivative · entry 9 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,200 Underlying: Common Stock · 47,200 shares Expires 2035-01-25 F8 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · derivative · entry 8 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,063 Underlying: Common Stock · 2,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F7 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F7 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 13,125 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · derivative · entry 7 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 13,125 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 1,058 | $38.01 | $40,214.58 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · nonDerivative · entry 5 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,629 F4 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · nonDerivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,125 | $37.87 | $194,102.71 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.485 to $38.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 8,000 | $36.94 | $295,531.20 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 13,125 | $30.69 | $402,806.25 |
DisclosureSEC source: 0001415889-25-002160 · form4-01282025_090140.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 01:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 1,123 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0001415889-25-001825 · form4-01222025_010141.xml · derivative · entry 6 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,615 Underlying: Common Stock · 1,123 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option shall vest with respect to 50% of the underlying shares on June 1, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on July 1, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 01:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,123 | $40.00 | $44,920.00 |
DisclosureSEC source: 0001415889-25-001825 · form4-01222025_010141.xml · nonDerivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 01:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 1,123 | $33.44 | $37,553.12 |
DisclosureSEC source: 0001415889-25-001825 · form4-01222025_010141.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2025 Filed Jan 22, 2025 01:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 29,475 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0001415889-25-001825 · form4-01222025_010141.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,738 Underlying: Common Stock · 29,475 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option shall vest with respect to 50% of the underlying shares on June 1, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on July 1, 2023. Read SEC document |
| January 16, 2025 Filed Jan 22, 2025 01:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 29,475 | $37.41 | $1,102,795.34 |
DisclosureSEC source: 0001415889-25-001825 · form4-01222025_010141.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.98. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2025 Filed Jan 22, 2025 01:44 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 29,475 | $33.44 | $985,644.00 |
DisclosureSEC source: 0001415889-25-001825 · form4-01222025_010141.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,507 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0001415889-25-001549 · form4-01162025_040101.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,213 Underlying: Common Stock · 10,507 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option shall vest with respect to 50% of the underlying shares on June 1, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on July 1, 2023. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 10,507 | $37.01 | $388,840.95 |
DisclosureSEC source: 0001415889-25-001549 · form4-01162025_040101.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.08. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,507 | $33.44 | $351,354.08 |
DisclosureSEC source: 0001415889-25-001549 · form4-01162025_040101.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 7,180 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0001415889-25-001489 · form4-01152025_040125.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,720 Underlying: Common Stock · 7,180 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option shall vest with respect to 50% of the underlying shares on June 1, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on July 1, 2023. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 7,180 | $37.04 | $265,946.48 |
DisclosureSEC source: 0001415889-25-001489 · form4-01152025_040125.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 7,180 | $33.44 | $240,099.20 |
DisclosureSEC source: 0001415889-25-001489 · form4-01152025_040125.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 21,496 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025826 · form4-10312024_081034.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,972 Underlying: Common Stock · 21,496 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 21,496 | $40.47 | $870,018.36 |
DisclosureSEC source: 0001415889-24-025826 · form4-10312024_081034.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.94. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 20:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 21,496 | $24.00 | $515,904.00 |
DisclosureSEC source: 0001415889-24-025826 · form4-10312024_081034.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 705 | $35.62 | $25,111.47 |
DisclosureSEC source: 0001415889-24-024813 · form4-10072024_081018.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.59 to $35.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 35,652 | $35.05 | $1,249,435.04 |
DisclosureSEC source: 0001415889-24-024813 · form4-10072024_081018.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.58 to $35.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:06 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 400 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024377 · form4-10022024_081008.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,468 Underlying: Common Stock · 400 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five qual annual installments beginning on August 21, 2021. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:06 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 400 | $40.19 | $16,076.92 |
DisclosureSEC source: 0001415889-24-024377 · form4-10022024_081008.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.45. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:06 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 400 | $24.00 | $9,600.00 |
DisclosureSEC source: 0001415889-24-024377 · form4-10022024_081008.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 35,846 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024179 · form4-10012024_081050.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,868 Underlying: Common Stock · 35,846 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five qual annual installments beginning on August 21, 2021. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 35,846 | $40.03 | $1,434,951.23 |
DisclosureSEC source: 0001415889-24-024179 · form4-10012024_081050.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.19. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 35,846 | $24.00 | $860,304.00 |
DisclosureSEC source: 0001415889-24-024179 · form4-10012024_081050.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024364 · form4-10022024_081008.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 23,643 | $40.00 | $945,720.00 |
DisclosureSEC source: 0001415889-24-024364 · form4-10022024_081008.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,357 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024364 · form4-10022024_081008.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2024 Filed Sep 30, 2024 20:03 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 200 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024089 · form4-09302024_080911.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,714 Underlying: Common Stock · 200 shares Expires 2030-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on August 21, 2021. Read SEC document |
| September 27, 2024 Filed Sep 30, 2024 20:03 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 200 | $40.05 | $8,009.00 |
DisclosureSEC source: 0001415889-24-024089 · form4-09302024_080911.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.09. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2024 Filed Sep 30, 2024 20:03 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 200 | $24.00 | $4,800.00 |
DisclosureSEC source: 0001415889-24-024089 · form4-09302024_080911.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:24 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 9,644 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-24-008350 · form4-03182024_110312.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,869 Underlying: Common Stock · 9,644 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on March 1, 2021. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:24 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 2,335 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-24-008350 · form4-03182024_110312.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,335 shares Expires 2029-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2019. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:24 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 11,979 | $32.00 | $383,328.00 |
DisclosureSEC source: 0001415889-24-008350 · form4-03182024_110312.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.06. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:24 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 11,979 | $8.22 | $98,467.38 |
DisclosureSEC source: 0001415889-24-008350 · form4-03182024_110312.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 21:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 94 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-24-007527 · form4-03112024_090322.xml · derivative · entry 4 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,513 Underlying: Common Stock · 94 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on March 1, 2021. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 21:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 100 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-24-007527 · form4-03112024_090322.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,335 Underlying: Common Stock · 100 shares Expires 2029-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2019. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 21:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 194 | $32.00 | $6,208.00 |
DisclosureSEC source: 0001415889-24-007527 · form4-03112024_090322.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: These shares were sold in a single transaction at a selling price of $32.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.